Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.
Formycon AG has acquired rights to two of Athos’ biosimilar candidates as part of a long-term strategic partnership between the two companies, in exchange for a consideration of approximately €650m ($725m).
Through the deal, Formycon will gain 100% of the rights to FYB202, a biosimilar candidate referencing Johnson & Johnson’s Stelara...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
